1. tion of radiolabeled amdoxovir, two main metabolites were identified: (unpublished data, RFS Pharma LLC, 2006). However, nucleotide
2. weeks (Margolis et al., 2007), none out of seven on amdoxovir up to clinical trials (unpublished data, RFS Pharma LLC, 2006).
3. under the curve minus baseline at day 15 as a response endpoint, it data, RFS Pharma LLC, 2006). The third phase I trial, DAPD-105, was designed to be an escalating combination was additive to synergistic against clinical isolates of HIV